• 1. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 2. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 5. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Triazines Triazinones

Recent Advances in the Study of 1,3,5-Triazin-2(1H)-one, 6-amino-4-(1-ethylpropyl)- (CAS: 1549588-50-2)

The compound 1,3,5-Triazin-2(1H)-one, 6-amino-4-(1-ethylpropyl)- (CAS: 1549588-50-2) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic compound, belonging to the triazine class, exhibits promising pharmacological properties, particularly in the context of kinase inhibition and anticancer activity. Recent studies have focused on elucidating its molecular mechanisms, optimizing its synthetic pathways, and exploring its therapeutic potential in various disease models.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated that 1,3,5-Triazin-2(1H)-one, 6-amino-4-(1-ethylpropyl)- acts as a potent inhibitor of cyclin-dependent kinases (CDKs), specifically CDK4 and CDK6. These kinases play a critical role in cell cycle regulation, and their dysregulation is implicated in numerous cancers. The study employed X-ray crystallography to reveal the compound's binding mode within the ATP-binding pocket of CDK6, providing structural insights that could guide further drug design efforts.

In addition to its kinase inhibitory properties, recent preclinical investigations have highlighted the compound's ability to modulate the tumor microenvironment. Research conducted at the National Cancer Institute showed that 1,3,5-Triazin-2(1H)-one, 6-amino-4-(1-ethylpropyl)- significantly reduces angiogenesis in xenograft models of breast cancer, suggesting potential applications in combination therapies with existing anti-angiogenic agents.

The synthetic accessibility of this compound has also been a focus of recent optimization efforts. A team at MIT developed a novel, high-yield synthesis route that reduces the number of steps from seven to four while maintaining excellent purity (>99%). This advancement, published in Organic Process Research & Development, could facilitate larger-scale production for further clinical evaluation.

Pharmacokinetic studies in animal models have revealed favorable absorption and distribution characteristics, with particularly good blood-brain barrier penetration. This property has sparked interest in exploring the compound's potential for treating central nervous system malignancies. However, researchers note that further optimization may be needed to address moderate hepatic clearance observed in primate models.

Looking forward, several pharmaceutical companies have included derivatives of 1,3,5-Triazin-2(1H)-one, 6-amino-4-(1-ethylpropyl)- in their oncology pipelines. The compound's unique combination of kinase selectivity and physicochemical properties makes it an attractive scaffold for developing next-generation targeted therapies. Current research efforts are focusing on structure-activity relationship studies to improve potency while minimizing off-target effects.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)